TerminatedNot Applicable

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Stopped: Development program terminated

United States22 participantsStarted 2021-05-05

Plain-language summary

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be willing and able to provide written informed consent * Age ≥ 18 years * Histologically- or cytologically-confirmed, relapsed/refractory, and metastatic or locally advanced head and neck, cervical, melanoma or non-small cell lung cancers. Other solid tumor types may be analyzed at the discretion of the Sponsor * Able to provide archived tumor tissue or have existing data on TAAs, HPV status or HLA sub-type * Willing to provide a saliva sample Exclusion Criteria: * There are no exclusion criteria for this study.

What they're measuring

Frequency of subjects with the expression of multiple tumor associated antigens and/or HPV-16 E6/E7.

Timeframe: 5 years

Trial details

NCT IDNCT05061940

SponsorRepertoire Immune Medicines

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-10-11

View on ClinicalTrials.gov More Head and Neck Cancer trials